Baxter adds Somatogen to artificial blood portfolio
This article was originally published in Clinica
Executive Summary
Baxter International has signed an agreement to acquire Somatogen in a stock merger worth an estimated $189 million. Somatogen is developing recombinant haemoglobin products and the acquisition will add to Baxter's expertise in the field of oxygen-carrying "blood substitutes".